HEALTH

Lilly, Mylan Reach Agreement: The Indianapolis-based drug maker said it and Mylan Laboratories Inc. will produce a generic form of its antibiotic Ceclor. The drug is one of the most popular in the world, but sales of the brand-name version have been falling since its patent ran out in December, 1992. Worldwide sales last year were about $910 million, down about 2%, according to estimates by securities firm Salomon Bros., which expects further declines. Like other drug makers whose products have lost patent protection, Eli Lilly & Co. hopes that selling a cheaper generic version will take back business from other generic drug makers.